JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset.

“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference. “I think we have an opportunity to develop a best-in-class product here for patients and move the standard of care ahead after 20 years.”